Processa Pharmaceuticals, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
George K Ng, Chief Executive Officer and a Director of Processa Pharmaceuticals, Inc., reported multiple transactions in common stock on August 8, 2026.
NASDAQ
Sheila Gujrathi, a Director of Processa Pharmaceuticals, Inc., reported multiple transactions in common stock on July 28, 2026.
NASDAQ
Justin W Yorke, a Director of Processa Pharmaceuticals, Inc., received 33,500 shares of common stock on July 26, 2026.
NASDAQ
Russell Skibsted, Chief Financial Officer of Processa Pharmaceuticals, Inc., received 11,883 shares of common stock on July 26, 2026.
NASDAQ
Geraldine Pannu, a Director of Processa Pharmaceuticals, Inc., received 33,500 shares of common stock on July 26, 2026.
NASDAQ
George K Ng, Chief Executive Officer and a Director of Processa Pharmaceuticals, Inc., received 9,384 shares of common stock on July 26, 2026.
NASDAQ
James R Neal, a Director of Processa Pharmaceuticals, Inc., received 62,221 shares of common stock on July 26, 2026.
NASDAQ
Patrick Lin, Chief Business - Strategy Off of Processa Pharmaceuticals, Inc., received 8,450 shares of common stock on July 26, 2026.
NASDAQ
Wendy Guy, Chief Administrative Officer of Processa Pharmaceuticals, Inc., received 9,450 shares of common stock on July 26, 2026.
NASDAQ
Khoso Baluch, a Director of Processa Pharmaceuticals, Inc., received 33,500 shares of common stock on July 26, 2026.
NASDAQ
Wendy Guy, Chief Administrative Officer of Processa Pharmaceuticals, Inc., acquired 2,436 shares of common stock on June 30, 2026.
NASDAQ
Patrick Lin, Chief Business Strategy Officer at Processa Pharmaceuticals, Inc., acquired 2,106 shares of common stock on June 30, 2026.
NASDAQ
Processa Pharmaceuticals, Inc. reports a Form 4 filing detailing the acquisition of common stock by its Chief Financial Officer, Russell Skibsted.
NASDAQ
David Young, Director and Officer at Processa Pharmaceuticals, acquired 2,531 shares of common stock on June 30, 2026, at a price of $1.93 per share.
NASDAQ
Justin W. Yorke, a Director at Processa Pharmaceuticals, Inc., acquired 203 shares of common stock through a time-based service award.
NASDAQ
Processa Pharmaceuticals, Inc. reports a Form 4 filing detailing a director's acquisition of company stock.
NASDAQ
Processa Pharmaceuticals, Inc. reports a Form 4 filing detailing a director's acquisition of common stock.
NASDAQ
Khoso Baluch, a Director at Processa Pharmaceuticals, Inc., acquired 203 shares of common stock through a time-based service award.
NASDAQ
David Young, a Director and Officer at Processa Pharmaceuticals, Inc., acquired 2,067 shares of common stock.
NASDAQ
Processa Pharmaceuticals' Chief Financial Officer, Russell Skibsted, has acquired 2,654 shares of common stock.
NASDAQ
Processa Pharmaceuticals reports a significant stock purchase by CEO George Ng, acquiring 2,465 shares at $2.22 each.
NASDAQ
Patrick Lin, Chief Business - Strategy Officer at Processa Pharmaceuticals, Inc., acquired 1,831 shares of common stock on June 15, 2026.
NASDAQ
Wendy Guy, Chief Administrative Officer of Processa Pharmaceuticals, Inc., acquired 2,118 shares of common stock on June 15, 2026, at a price of $2.22 per share.
NASDAQ
David Young, President of R&D at Processa Pharmaceuticals, acquired 1,786 shares of common stock at $2.57 per share.
NASDAQ
Processa Pharmaceuticals CFO Russell Skibsted acquired 2,292 shares of common stock at $2.57 per share.
NASDAQ
Processa Pharmaceuticals CEO George Ng acquired 2,129 shares of common stock at $2.57 per share.
NASDAQ
Chief Business and Strategy Officer Patrick Lin acquired 1,582 shares of Processa Pharmaceuticals common stock.
NASDAQ
Chief Administrative Officer Wendy Guy acquired 1,829 shares of Processa Pharmaceuticals common stock at $2.57 per share.
NASDAQ
Processa Pharmaceuticals CEO George Ng acquired 1,843 shares of common stock at $2.97 per share.
NASDAQ
Processa Pharmaceuticals President of R&D David Young acquired 1,545 shares of common stock at $2.97 per share.